understanding variant histologies in urothelial carcinoma: io and cabozantinib's potential
Published 1 year ago • 36 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:34
arcadia: evaluating durvalumab and cabozantinib in variant histology tumors
-
3:55
comparing ici outcomes in upper and lower tract urothelial carcinoma
-
2:21
precision medicine in urothelial carcinoma
-
4:00
overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
-
1:26
management of urothelial carcinoma with positive pelvic/retroperitoneal lymph nodes
-
13:57
differences and challenges diagnosing upper tract urothelial carcinoma
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
1:17
recent advances in the treatment of upper tract urothelial carcinoma
-
40:58
urothelial carcinoma: advances in immuno-oncology
-
1:22
addressing unmet needs in metastatic urothelial carcinoma
-
1:04
treatment considerations for patients with metastatic urothelial carcinoma
-
2:01
immune checkpoint inhibitors in urothelial bladder cancer
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
2:43
pembrolizumab: defining standards of care in urothelial cancer
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
1:40
dr. petrylak on trial of atezolizumab in urothelial carcinoma
-
1:03
dr. pal on the sequencing of immunotherapy for urothelial carcinoma
-
2:17
optimizing treatment options for patients with muscle-invasive urothelial carcinoma
-
1:34
phase 2 trial of cv301 vaccine plus atezolizumab in advanced urothelial carcinoma